Evolva SA of Switzerland has raised an additional CHF 21 million (€13.9 million) to finance its takeover of Arpida Ltd, creating a new publicly-listed company with a technology platform that uses synthetic biology to create new small molecule drugs.
Evolva SA of Switzerland has raised an additional CHF 21 million (€13.9 million) to finance its takeover of Arpida Ltd, creating a new publicly-listed company with a technology platform that uses synthetic biology to create new small molecule drugs.